Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ: NTRB, NTRBW) is a developer of prescription transdermal pharmaceutical products, with a primary focus on its AVERSA abuse-deterrent transdermal technology and its lead product candidate, an abuse-deterrent fentanyl patch. The Nutriband news stream highlights how the company is advancing this technology platform, interacting with regulators, and managing its corporate structure to support product development.
Readers of the Nutriband news page can follow regulatory and clinical development updates, including the company’s reported meetings with the U.S. Food and Drug Administration on the Chemistry, Manufacturing, and Controls plans and the 505(b)(2) NDA pathway for AVERSA Fentanyl. News items also cover Nutriband’s summaries of FDA feedback on in vitro studies to characterize abuse-deterrent properties and its intention to move toward an IND filing in support of a Human Abuse Potential clinical study.
The company’s releases also describe intellectual property developments, such as a provisional patent application to enhance AVERSA technology and U.S. patent actions related to abuse and misuse deterrent transdermal systems, alongside references to a broad patent portfolio covering AVERSA in multiple countries. Corporate and capital markets news includes announcements of a preferred stock dividend tied to future FDA approval of AVERSA Fentanyl, the sale of a majority stake in subsidiary Pocono Pharmaceutical to EarthVision Bio, and Nutriband’s inclusion in Russell indexes.
Additional coverage includes partnership and collaboration news, such as agreements with Kindeva Drug Delivery for product development, Brand Institute for commercial brand name creation, and a non-binding Letter of Intent with the Qvanta Group to explore advanced technology support for abuse-deterrent pharmaceutical innovation. Investors and observers can use this page to review how Nutriband presents its progress on AVERSA Fentanyl, its stance on issues like illicit versus prescription fentanyl, and its participation in investor conferences and public communications.
Nutriband (NASDAQ:NTRB) has announced key dates for its upcoming 25% preferred stock dividend. Shareholders of record as of July 25th, 2025 will receive one preferred share for every four common shares held, with the distribution set for August 5th.
The preferred shares come with two key features: they will be convertible to common stock upon FDA approval of the company's AVERSA Fentanyl product, and if not converted, shareholders will be entitled to an annual cash dividend from company profits, as determined by the Board of Directors.
Nutriband (NASDAQ:NTRB) has declared a 25% preferred stock dividend, where shareholders will receive one preferred share for every four common shares held as of July 25th, 2025, with distribution set for August 5th. The preferred shares are convertible to common stock upon FDA approval of AVERSA Fentanyl product.
These preferred shares will be eligible for annual cash dividends from company profits if not converted. CEO Gareth Sheridan emphasized the company's focus on shareholder value creation and highlighted recent progress with Kindeva on commercialization manufacturing as they prepare for FDA approval submission.
Nutriband Inc. (NASDAQ:NTRB) has achieved a significant milestone with its inclusion in four Russell indexes: the Russell Microcap Index, Russell Microcap Growth Index, Russell 3000E Index, and Russell 3000E Growth Index as part of the 2025 Russell indexes reconstitution.
CEO Gareth Sheridan highlighted the company's AVERSA pipeline development, particularly AVERSA Fentanyl, which has a projected peak annual US sales potential of $80 million to $200 million. The company aims to enhance the safety profile of easily abused medications while ensuring availability to patients in need.
The Russell indexes, which serve as benchmarks for approximately $10.6 trillion in assets as of June 2024, are widely utilized by investment managers and institutional investors for index funds and active investment strategies. FTSE Russell will transition to a semi-annual reconstitution frequency starting in 2026.
Nutriband CEO Gareth Sheridan released a shareholder letter highlighting the company's achievements in 2024 and outlook for 2025. The company is developing AVERSA technology, aimed at creating the world's first abuse-deterrent transdermal drug delivery system.
In partnership with Kindeva Drug Delivery, Nutriband is developing AVERSA Fentanyl, projected to reach peak annual sales of $80M-$200M. Their second product, AVERSA Buprenorphine, is estimated to achieve $70M-$130M in peak annual sales. The company secured $8.4M through private placement in April 2024 and expanded its patent portfolio to 46 countries.
Key 2025 objectives include:
- Conducting Human Abuse Liability clinical trials for AVERSA Fentanyl
- Filing an Investigational New Drug application with FDA
- Exploring international partnerships
- Growing revenue through Pocono Pharma subsidiary's kinesiology tape manufacturing
Nutriband Inc. (NASDAQ:NTRB) has secured a patent in Macao for its AVERSA abuse deterrent transdermal technology. The patent, J/9010, was granted on February 11, 2025, protecting the company's 'Abuse and Misuse Deterrent Transdermal Systems.'
AVERSA technology is now protected by patents in 46 countries, including major markets like the US, Europe, Japan, and China. The technology incorporates aversive agents into transdermal patches to prevent abuse of drugs with high abuse potential, such as opioids and stimulants.
The company is collaborating with Kindeva Drug Delivery to develop AVERSA Fentanyl, potentially the first abuse-deterrent opioid patch globally. The product aims to deter abuse and reduce accidental exposure risks, with projected peak annual US sales between $80 million to $200 million.
Nutriband Inc. (NASDAQ:NTRB) has announced signing an Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which they position as potentially becoming the world's first abuse deterrent patch platform for chronic pain management.